Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209530 · ClinicalTrials.gov registry record · Phase 2
Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04209530: Clinical Trial Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT04209530 is a Phase 2 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04209530, a Phase 2 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic Panniculopathy (EFP).
Primary Outcome
Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-point photonumeric scale rating cellulite severity from "0" (None) to "4" (Severe) from a patient's perspective
Interventions
- DRUG EN3835
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2020-10-05 |
| Phase | Phase 2 |
Why NCT04209530 stopped before completion
NCT04209530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which EN3835 is the first listed.
NCT04209530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04209530 about?
NCT04209530 is a clinical study titled "Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women". This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic Panniculopathy (EFP).
What is the current status of trial NCT04209530?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-11-20. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT04209530?
The interventions under investigation include: EN3835 (DRUG).
Who is sponsoring clinical trial NCT04209530?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04209530's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI